New drug oxacom® shows promise for treating rare lung condition
NCT ID NCT06683040
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, Oxacom®, in 200 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. The drug is given in different doses to see if it can lower pressure in the lung's blood vessels better than a placebo. The goal is to control the disease and improve daily life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NMCRCardiologyRu
Moscow, 121552, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a smartwatch replace the clinic walk test for lung disease patients?
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests